EP Patent

EP1148873A2 — Highly purified ethyl epa and other epa derivatives for psychiatric and neurological disorders

Assigned to Amarin Neuroscience Ltd · Expires 2001-10-31 · 25y expired

What this patent protects

A pharmaceutical preparation comprising EPA in an appropriately assimilable form, for example in the form of the ehtyl ester, where of all the fatty acids present in the preparation at least 90 %, and preferably at least 95 %, is in the form of EPA and where less than 5 %, and pr…

USPTO Abstract

A pharmaceutical preparation comprising EPA in an appropriately assimilable form, for example in the form of the ehtyl ester, where of all the fatty acids present in the preparation at least 90 %, and preferably at least 95 %, is in the form of EPA and where less than 5 %, and preferably less than 3 %, is in the form of DHA is provided for the treatment of a psychiatric or central nervous disorder. The preparation may be administered with conventional drugs to treat psychiatric or central nervous disorders, like schizophrenia, bipolar disorders, attention deficit, hyperactivity disorder, dementia, panic and anxiety disorders.

Drugs covered by this patent

Patent Metadata

Patent number
EP1148873A2
Jurisdiction
EP
Classification
—
Expires
2001-10-31
Drug substance claim
No
Drug product claim
No
Assignee
Amarin Neuroscience Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.